Abstract

This clinical contract supports the design and conduct of Phase I/II clinical trials of monoclonal antibodies, immunoconjugates and other targeting agents alone or in combination with other investigational or standard therapy. This is a shared contract between the Division of Cancer Treatment, Biological Resources Branch, and the Cancer Therapy Evaluation Branch. These trials will focus on studies of mechanisms of anti-tumor response and immune modulation. Current areas of emphasis include the elucidation of complex interactions between the biological agent(s), the host effector cells and the tumor which may lead to tumor regression. Thus, ADCC, TIL activation, and the induced inflammatory response will be under scrutiny. In addition, detailed studies will be performed of pharmacokinetics and biodistribution, which are intended to lead to better application of monoclonal antibodies to deliver radionuclides, toxins and drugs to tumor cell targets. Of special interest will be the influence on these processes of specific modifications of monoclonal antibodies, such as changes in affinity, isotype, chimerization and substitution of F(ab')2 fragments.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM097611-005
Application #
3616795
Study Section
Project Start
1989-03-31
Project End
1994-03-30
Budget Start
1991-08-01
Budget End
1992-03-08
Support Year
Fiscal Year
1991
Total Cost
Indirect Cost

  Institution

Name
University of Alabama Birmingham
Department
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294

  Publications

Meredith, Ruby F; Buchsbaum, Donald J; Alvarez, Ronald D et al. (2007) Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 13:5643s-5645s
Saleh, M N; Tilden, A B; Meredith, R F et al. (1998) Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy. Biotech Histochem 73:186-97
Saleh, M N; Goldman, S J; LoBuglio, A F et al. (1995) CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 85:2910-7
Saleh, M N; Khazaeli, M B; Wheeler, R H et al. (1995) Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. Cancer Res 55:4339-46
Saleh, M N; Khazaeli, M B; Grizzle, W E et al. (1993) A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res 53:4555-62
Meredith, R F; Khazaeli, M B; Grizzle, W E et al. (1993) Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Hum Antibodies Hybridomas 4:190-7
Meredith, R F; Johnson, T K; Plott, G et al. (1993) Dosimetry of solid tumors. Med Phys 20:583-92
Saleh, M N; Stapleton, J D; Khazaeli, M B et al. (1993) Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 151:3390-8
Cartner, A M; Conry, R M; Safavy, A et al. (1993) An animal model to predict the immunogenicity of murine V regions in humans. Hum Antibodies Hybridomas 4:174-80
Conry, R M; Khazaeli, M B; LoBuglio, A F (1992) Lack of T-cell immunity in humans with preexisting anti-mouse immunoglobulin reactivity. Cancer Res 52:6979-82

Showing the most recent 10 out of 11 publications